Loading…
Employees: 1,310
Size Supriya Lifescience (SUPRIYA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $593M, the 780th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹695.80 on 6 Nov 2026.
Performance Over six months the shares fell 0.8%, against -22.1% for the median peer and 0.0% for the India market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 28.1% over the last twelve months (peer median -1.7%); the operating margin is 29.7% (peer median 4.3%).
Valuation It trades at 23.6× forward earnings against a peer median of 10.9× (4th most expensive of 10).
Price implies For today's price to make sense, revenue must grow about 28% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.9 points above its cost of capital (14.3% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹8.73B | ₹8.02B | ₹6.80B | ₹5.57B | ₹4.50B |
| Revenue growth | — | +18% | +22% | +24% | — |
| Gross profit | ₹4.61B | ₹3.22B | ₹2.96B | ₹1.97B | ₹1.54B |
| EBITDA | ₹2.90B | ₹2.81B | ₹2.55B | ₹1.69B | ₹1.27B |
| Net income | ₹1.98B | ₹2.09B | ₹1.88B | ₹1.19B | ₹899M |
| Free cash flow | n/a | ₹430M | ₹102M | -₹223M | -₹358M |
| Capital expenditure | n/a | ₹1.52B | ₹1.62B | ₹1.46B | ₹1.08B |
| Total debt | n/a | ₹54.4M | ₹53.8M | ₹54.9M | ₹225M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SUPRIYA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -21.8% | -6.4% | 3rd lowest of 21 |
| 6-month return | -0.8% | -22.1% | 6th highest of 21 |
| Distance from 52-week high | -35.9% | -36.1% | 11th highest of 21 |
| Revenue growth (TTM) | +28.1% | -1.7% | 4th highest of 18 |
| Operating margin | 29.7% | 4.3% | 3rd highest of 18 |
| Forward P/E | 23.6× | 10.9× | 4th most expensive of 10 |
| Growth the price implies (Req g, 7 yrs) | 27.9% | 0.9% | most demanding of 9 |
| Growth delivered (Del g) | +15.8% | +5.8% | 2nd highest of 9 |
| Hurdle (Req g minus delivered) | +12.1 pp | -6.7 pp | most demanding of 9 |
| ROIC minus cost of capital | +1.9 pp | -2.1 pp | 6th highest of 17 |
| EV / EBITDA | 19.3× | 15.2× | 3rd most expensive of 6 |
| Net debt / EBITDA | -0.2× | 1.3× | 2nd least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Supriya Lifescience SUPRIYA.NS | India | $593M | -1% | +28% | 30% | 23.6× | 27.9% | +15.8% |
| TTY Biopharm 4105.TWO | Taiwan | $596M | +7% | +5% | 33% | 10.9× | -11.1% | +8.8% |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $598M | -23% | -3% | 7% | 9.7× | -3.2% | +4.1% |
| Abbisko Cayman 2256.HK | Hong Kong | $589M | -48% | -83% | -520% | n/a | n/a | n/a |
| Jinhe Biotechnology 002688.SZ | China | $587M | -22% | +9% | 5% | 9.5× | 14.8% | +9.7% |
| Jinling Pharmaceutical 000919.SZ | China | $586M | -14% | -8% | 1% | n/a | 5.0% | +5.0% |
| Aclaris Therapeutics ACRS | United States | $604M | -21% | -51% | -1,040% | n/a | n/a | n/a |
| Chongkundang 185750.KS | South Korea | $611M | -26% | +7% | 4% | 12.6× | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $573M | -25% | +32% | 17% | n/a | 5.5% | -1.1% |
| Bicara Therapeutics BCAX | United States | $572M | -62% | n/a | n/a | n/a | n/a | n/a |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $617M | -22% | -21% | 32% | 10.9× | -14.3% | +2.8% |
| Innova Captab INNOVACAP.NS | India | $618M | +18% | +34% | 12% | 30.4× | 25.4% | +31.4% |
| Senores Pharmaceuticals SENORES.NS | India | $566M | +25% | +40% | 24% | 34.2× | n/a | n/a |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $566M | -28% | -11% | -8% | n/a | n/a | n/a |
| Zhong Zhu Healthcare 600568.SS | China | $628M | -21% | -6% | -34% | n/a | n/a | n/a |
| Ovid Therapeutics OVID | United States | $557M | +2% | -76% | -3,687% | n/a | n/a | n/a |
| DBV Technologies DBV.PA | France | $633M | -47% | n/a | n/a | n/a | n/a | n/a |
| Chimin Health Management 603222.SS | China | $553M | -28% | +1% | -28% | n/a | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $638M | -12% | -2% | 8% | 7.1× | -4.9% | +6.5% |
| Orchid Pharma ORCHPHARMA.NS | India | $551M | +27% | +11% | 0% | 75.5× | n/a | n/a |
| Olema Pharmaceuticals OLMA | United States | $641M | -51% | n/a | n/a | n/a | n/a | n/a |